Saenz-Antoñanzas Ander, Auzmendi-Iriarte Jaione, Carrasco-Garcia Estefania, Moreno-Cugnon Leire, Ruiz Irune, Villanua Jorge, Egaña Larraitz, Otaegui David, Samprón Nicolás, Matheu Ander
Cellular Oncology group, Biodonostia Health Research Institute, E-20014 San Sebastian, Spain.
CIBER de Fragilidad y Envejecimiento Saludable (CIBERfes), 28029 Madrid, Spain.
Cancers (Basel). 2019 Jul 5;11(7):950. doi: 10.3390/cancers11070950.
Liquid biopsy represents a minimally invasive procedure that can provide similar information from body fluids to what is usually obtained from a tissue biopsy sample. Its implementation in the clinical setting might significantly renew the field of medical oncology, facilitating the introduction of the concepts of precision medicine and patient-tailored therapies. These advances may be useful in the diagnosis of brain tumors that currently require surgery for tissue collection, or to perform genetic tumor profiling for disease classification and guidance of therapy. In this review, we will summarize the most recent advances and putative applications of liquid biopsy in glioblastoma, the most common and malignant adult brain tumor. Moreover, we will discuss the remaining challenges and hurdles in terms of technology and biology for its clinical application.
液体活检是一种微创程序,它能够从体液中提供与通常从组织活检样本中获得的信息相似的信息。其在临床环境中的应用可能会显著革新医学肿瘤学领域,促进精准医学和患者定制疗法概念的引入。这些进展可能有助于诊断目前需要手术获取组织的脑肿瘤,或进行肿瘤基因分析以用于疾病分类和治疗指导。在本综述中,我们将总结液体活检在胶质母细胞瘤(最常见且恶性程度最高的成人脑肿瘤)方面的最新进展和潜在应用。此外,我们还将讨论其临床应用在技术和生物学方面尚存的挑战与障碍。